PRAX
Praxis Precision Medicines, Inc. Common Stock
Nasdaq · usd
Praxis Precision Medicines, Inc. Common Stock (PRAX) trades at $312.49 (+2.44%) as of 5:24:52 AM EST on Nov 19, 2026, +15.39% over the past month. Market cap is $8.53B, with 8.7 days to cover in short interest.
Stock performance
How Praxis Precision Medicines, Inc. Common Stock (PRAX) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.04%
- 1W
- -11.85%
- 1M
- +15.39%
- YTD
- +3.55%
- 1Y
- +85.99%
- 52-wk range
- $160.11 – $392.70
Key statistics
Today's trading snapshot for PRAX: day range, open, previous close, volume and market cap.
- Day range
- $302.82 – $314.72
- Open
- $304.36
- Prev close
- $305.06
- Volume
- 425.75K
- Market cap
- $8.53B
- Shares out
- 27.95M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Praxis Precision Medicines, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 6.77
- P/FCF
- —
- ROE
- -28.5%
- ROA
- -27.4%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Praxis Precision Medicines, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Partnership or collaborationNov 12, 2026
The Company continues to make progress on its recent collaboration with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide. The patch is designed to improve accessibility for ulixacaltamide and is planned to enter the clinic in 2027.
- Quarterly earningsNov 9, 2026
On November 9, 2026, Praxis Precision Medicines, Inc. announced its financial results for the quarter ended September 30, 2026.
- Investor presentationAug 6, 2026
On August 6, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available in the "Investors + Media" portion of the Company's website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.2 to this Current Report.
- Partnership or collaborationJul 7, 2026
the Company entered into a research collaboration and license agreement (the "Agreement") with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems ("Remagine"), to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor. Under the Agreement, the Company and Remagine will collaborate to apply Remagine's proprietary platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide
- New auditor engagementJul 2, 2026
On June 29, 2026, the Audit Committee approved the engagement of KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm, effective as of that date.
Dividend history and stock splits
Praxis Precision Medicines, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-15Nov 29, 2023
PRAX short interest
How heavily PRAX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.7
- Short interest
- 4.21M
- Avg volume
- 484.39K
As of · reported to FINRA twice monthly.
PRAX news
The latest news and headlines about Praxis Precision Medicines, Inc. Common Stock (PRAX).
- Why Is Praxis Precision Stock Soaring Tuesday?positiveBenzinga· Apr 14, 2026
- Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathypositiveGlobeNewswire Inc.· Apr 6, 2026
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterpositiveThe Motley Fool· Mar 16, 2026
- Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its PipelinepositiveThe Motley Fool· Mar 13, 2026
- Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA FilingspositiveThe Motley Fool· Mar 13, 2026
Frequently asked questions
What is the Praxis Precision Medicines, Inc. Common Stock (PRAX) stock price today?
Praxis Precision Medicines, Inc. Common Stock (PRAX) is trading at $312.49 (+2.44% on the day) as of 5:24:52 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Praxis Precision Medicines, Inc. Common Stock?
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance.
What is the short interest in PRAX?
As of Oct 30, 2026, PRAX has 4.21M shares short and 8.7 days to cover.
What exchange is PRAX listed on?
Praxis Precision Medicines, Inc. Common Stock (PRAX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of PRAX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a PRAX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.